FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      
           
This page is updated frequently with new Rheumatoid Arthritis-related patent applications. Subscribe to the Rheumatoid Arthritis RSS feed to automatically get the update: related Rheumatoid RSS feeds. RSS updates for this page: Rheumatoid Arthritis RSS RSS


Date/App# patent app List of recent Rheumatoid Arthritis-related patents
01/22/15
20150025066
 Cyclic diaminopyrimidine derivatives patent thumbnailCyclic diaminopyrimidine derivatives
In which a, l1, l2, x and y have the meanings indicated in claim 1, are inhibitors of syk, and can be employed, inter alia, for the treatment of rheumatoid arthritis.. .
01/22/15
20150025058
 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors patent thumbnail8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
Are inhibitors of syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and/or systemic lupus. .
01/22/15
20150025056
 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases patent thumbnailSubstituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
Its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring a substituent groups are fully defined in the following disclosure. The compounds of formula i are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of mmps is desirable..
01/22/15
20150025050
 Corticosteroids for the treatment of joint pain patent thumbnailCorticosteroids for the treatment of joint pain
Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
Flexion Therapeutics, Inc.
01/22/15
20150024075
 Phytocomposition for the treatment of pain related to joint diseases patent thumbnailPhytocomposition for the treatment of pain related to joint diseases
It is disclosed a phytocomposition which includes: (a) 0.01 wt % to 26 wt % of arnica montana extract; (b) 0.01 wt % to 26 wt % of rosmarinus officinalis extract; (c) 0.01 wt % to 26 wt % of zingiber officinale extract; and (d) 0.01 wt % to 26 wt % of boswellia serrate extract. Said phytocomposition can be used in combination with a pharmaceutically acceptable carrier in order to obtain a pharmaceutical composition that can be used for treating muscle, arthritic and rheumatic pain in a patient, caused by joint diseases, in particular rheumatoid arthritis, osteoarthritis, fibromyalgia, gouty arthritis, psoriatic arthritis, lupus and juvenile arthritis..
01/15/15
20150018347
 Spirocyclic compounds as modulators of chemokine receptor activity patent thumbnailSpirocyclic compounds as modulators of chemokine receptor activity
Or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
01/15/15
20150017266
 Compositions and methods for relieving symptoms of rheumatoid arthritis and related illnesses patent thumbnailCompositions and methods for relieving symptoms of rheumatoid arthritis and related illnesses
Compositions and methods for relieving symptoms of rheumatoid arthritis (ra) and related illnesses are disclosed. It appears that the primary cause of ra is a sensitivity or hypersensitivity to potassium and/or vitamin c, or too much potassium and/or vitamin c in the diet.
01/08/15
20150011767
 Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints patent thumbnailUse of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints
The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University
01/08/15
20150010627
 New pharmaceutical compositions of flurbiprofen and glucosamin patent thumbnailNew pharmaceutical compositions of flurbiprofen and glucosamin
The present invention relates to new pharmaceutical compositions of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to new pharmaceutical compositions for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis..
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
01/08/15
20150010573
 Il-17 antibody formulation patent thumbnailIl-17 antibody formulation
The present invention provides stabilized pharmaceutical formulations for anti-il-17 antibodies, comprising e.g. Citrate, sodium chloride and polysorbate-80 at ph 5.7.
Eli Lilly And Company
12/25/14
20140378537

Treatment of th17 mediated inflammatory diseases


The present invention provides methods and means to reduce inflammation associated with irf-4, ap-1 and th17 mediated diseases. In particular, the invention provides methods and means to treat multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis and related conditions..
Genentech, Inc.
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140378453

2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors


The present invention relates to novel inhibitors of factors viia, ixa, xa, xia, in particular factor viia, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed..
Pharmacyclics, Inc.
12/25/14
20140378384

Polypeptides in preparation of drugs for treatment or prevention of rheumatoid arthritis


A series of polypeptides presenting high integrin affinity and bonding capacity is provided. Three polypeptides among said series can be adopted in prevention and treatment of rheumatoid arthritis.
12/25/14
20140377387

Compositions and methods for modulating lipid composition


This disclosure relates to novel herbal compositions comprising extracts of rosemary and oregano, and methods of using the herbal compositions to modulate inflammatory potential. One or both of the extracts may be supercritical extracts.
Board Of Regents Of The University Of Texas System
12/25/14
20140377282

Anti-kdr antibodies and methods of use


The present invention provides anti-kdr monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant vegf or kdr expression and/or activity.. .
Apexigen, Inc.
12/18/14
20140371250

Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors


The present invention relates to chemical compounds of formula (i) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by tnf-α or by pde4, including but not limited to rheumatoid arthritis.. .
High Point Pharmaceuticals, Llc
12/18/14
20140371242

Azathioprine oral suspensions and methods of use


Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
12/11/14
20140364401

Antispasmodic 1,2-diols and 1,2,3-triols


The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
12/11/14
20140363497

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
12/04/14
20140356437

Corticosteroids for the treatment of joint pain


Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
12/04/14
20140356391

Amino acid sequences for clinical remission of psoriasis and related diseases.


Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of cutaneous leishmaniasis, psoriasis, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, seborrheic dermatitis and skin papilloma. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells.
11/27/14
20140349998

Pyrrolopyrimidines as janus kinase inhiitors


The instant invention provides compounds of formula i which are jak3 inhibitors. Specifically, the compounds of formula i are pyrrolo[2,3-d]pyrimidine derivative compounds.
11/27/14
20140349989

Compounds and therapeutic uses thereof


The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, t-cell mediated autoimmune disease, ischemia, and complications associated with these diseases and disorders.. .
11/27/14
20140349980

Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage


The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.. .
11/27/14
20140348784

Compositions and methods for treatment of angiogenesis in pathological lesions


Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions.
11/20/14
20140342378

Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis


The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue.
11/20/14
20140341887

Methods for treating, diagnosing, and monitoring rheumatoid arthritis


Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents..
11/13/14
20140336162

Locally administrated low doses of corticosteroids


This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot..
11/13/14
20140336121

Factor h for treatment of rheumatoid arthritis


The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising factor h (fh). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the factor h..
11/13/14
20140336069

Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit


Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.. .
11/13/14
20140335081

Treatment for rheumatoid arthritis


Treatment of rheumatoid arthritis (ra) to provide clinical benefit in patients, including decrease in das28-crp by more than 1.2 and/or improvement determined by acr20, acr50 or acr70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to tyr-leu-asp-phe-gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (gm-csfrα). Use of gm-csfrα inhibitors such as mavrilimumab to enhance clinical benefit in ra patients receiving stable dose of dmards, particularly methotrexate..
11/06/14
20140329815

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
11/06/14
20140329799

Aminopyrimidinones as interleukin receptor-associated kinase inhibitors


This invention relates to aminopyrimidinone compounds of formula (i) that are inhibitors of interleukin receptor-associated kinases, in particular irak-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.. .
10/30/14
20140322757

Antibodies that bind colony stimulating factor 1 receptor (csf1r)


Antibodies that bind csf1r are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind csf1r are also provided.
10/30/14
20140322274

Therapeutic agents


A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside gm-1 associated activity in an amount effective to treat the disease.. .
10/30/14
20140322239

Anti-il-6 receptor antibodies and methods of use


The present invention provides anti-il-6r monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.. .
10/30/14
20140322211

Tenascin-c and use thereof in rheumatoid arthritis


The present invention provides a method of determining the rheumatoid arthritis status of a subject, or the progression of rheumatoid arthritis, or the appropriate treatment for a subject with rheumatoid arthritis, comprising the steps of (a) determining the level of tenascin-c in a sample from said subject; and (b) comparing the level of tenascin-c determined in step (a) with one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis.
10/23/14
20140316106

Integrin-blocking polypeptides and uses thereof


A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis.
10/23/14
20140315909

3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h- pyrrolo[2,3-b]pyrazine dual itk and jak3 kinase inhibitors


Salts thereof, their synthesis, and their use as itk and jak3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention..
10/23/14
20140315889

Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof


The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against histone deacetylase (hdac), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against histone deacetylase (hdac) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease..
10/23/14
20140315888

Novel heterocyclic derivatives and their uses


The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type i) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer..
10/23/14
20140314866

Materials and methods for modulating immune responses


The present invention provides nanoparticle-coupled tolerogenic treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (sle), multiple sclerosis (ms), inflammatory bowel disease (ibd), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with graft versus host disease (gvhd) following hematopoietic stem cell transplantation..
10/23/14
20140314741

Human antibody against interleukin-20 and treatment for inflammatory diseases


Flb5m5 is a humanized monoclonal antibody with three mutated amino acids in the cdrs relative to its parental mouse anti-il-20 monoclonal antibody 7e and five mutated amino acids of the light-chain framework region relative to the amino acids of the light-chain framework region of human vκ2. Flb5m5 not only retains binding specificity toward il-20 but also has a better binding affinity than 7e for il-20.
10/09/14
20140303902

Methods, system, and medium for associating rheumatoid arthritis subjects with cardiovascular disease


The present invention relates to a system and a medium for analyzing one or more analytes in rheumatoid arthritis subjects to determine whether the subject is at increased risk of diseases such as a cardiovascular disease, the subject's current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in the subject. In addition, the present invention further provides methods for analyzing data to determine risk of cardiovascular disease, current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in a rheumatoid arthritis subject..
10/09/14
20140303142

Azaindoles as janus kinase inhibitors


The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
10/09/14
20140302053

Compositions for the treatment of rheumatoid arthritis and methods of using same


The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r) with a dmard.. .
10/02/14
20140294897

Potent lna oligonucleotides for the inhibition of hif-1a expression


The present disclosure relates to an lna oligonucleotide consisting of a sequence selected from the group consisting of 5′-(tx)gxgxcsasasgscsastscscstxgxt-3′ and 5′-(gx)txtxascstsgscscststscstxtxa-3′, wherein capital letters designate a beta-d-oxy-lna nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-d-oxy-lna nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/lna nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/lna nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The lna oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (hif-1a), e.g.
10/02/14
20140294856

Combination treatment comprising a hdac6 inhibitor and an akt inhibitor


The invention provides compositions comprising a histone deacetylase 6 (hdac6) inhibitor and an akt inhibitor, pharmaceutical compositions/formulations and kits of parts comprising the same; optionally further comprising one or more anti-cancer agents. The compositions of the invention provide for surprisingly efficacious killing of inter alia, cancer cells.
09/25/14
20140288011

Genetic association


This invention is directed in part to methods, assays and/or kits for identifying an individual who has an autoimmune disease (such as rheumatoid arthritis), or who has an altered risk for having or developing the autoimmune disease. The methods in one aspect comprise determining the presence or absence of a nucleic acid variant within the somatostatin receptor type 2 (sstr2) gene in the individual's nucleic acids, wherein the presence of the nucleic acid variant is correlated with having the autoimmune disease or the altered risk.
09/18/14
20140277220

Heated garment for medical applications


A patient-treatment system and related method provide relief from, and treatment for, muscle spasticity disorders, willis-ekbom disease, contracture, sleep onset insomnia, sleep maintenance insomnia, rheumatoid arthritis, and other similar disorders by applying controlled heat, and optionally muscle monitoring/stimulation, to one or more parts of a patient's body.. .
09/18/14
20140275203

Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof


The present invention is for method of treating metabolic bone disease, new compounds and pharmaceutical compositions comprising the active ingredients having inhibition effects on osteoclast differentiation. The pharmaceutical composition comprising new compounds according to the present invention can be used as medicines for treating metabolic bone diseases such as bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone, and paget's disease..
09/18/14
20140271645

Method for treating inflammation


A method for treating il-20 induced inflammation. An antagonist to il-20 is administered to treat inflammation and associated diseases.
09/18/14
20140271630

Rituximab induction therapy followed by glatiramer acetate therapy


The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, crohn's disease, or systemic lupus erythematosus..
09/11/14
20140255957

Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis


The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.. .
09/11/14
20140255422

Antibodies that bind to il-23


The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome.
09/11/14
20140255406

Anti-tnf-anti-il-17 bispecific antibodies


Bispecific antibodies are provided that specifically bind both tumor necrosis factor alpha (tnfα) and interleukin-17 (il-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including rheumatoid arthritis (ra), psoriatic arthritis (psa), and ankylosing spondylitis (as)..
09/11/14
20140255390

Method of treating rheumatoid arthritis with an anti-il-6r antibody


The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hil-6r). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (nsaid), a glucocorticoid, a disease-modifying anti-rheumatic drug (dmard), or a tnf-alpha antagonist, t-cell blocker, anti-cd20 antibody, an il-1, jak or il-17 antagonist, or any combination thereof..
09/11/14
20140255310

Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression


The present invention relates to methods of using a g protein-coupled receptor (gpcr) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the gpcr couples to gi.
09/04/14
20140249130

Bipyridylaminopyridines as syk inhibitors


The present invention provides novel pyrimidine amines of formula i which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd and rheumatoid arthritis and cancer.. .
09/04/14
20140248265

Therapeutic antibodies binding il 12rbeta1


The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of the heterodimeric il12 receptor (together with il12rβ2 chain) as well as il23 receptor (together with il23rα chain). The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifny production of t cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifny production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
08/28/14
20140243382

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
08/28/14
20140243309

Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors


The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/28/14
20140243301

Chlorobis copper (i) complex compositions and methods of manufacture and use


A method of manufacturing an anhydrous copper complex of formula c12h10cicun2o4 and methods of treating neur-muscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (gp), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention..
08/28/14
20140243290

Aminopyrimidines as syk inhibitors


The present invention provides novel pyrimidine amines of formula (i) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd and rheumatoid arthritis.. .
08/28/14
20140243273

Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor


The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a compound of formula i and an optional co-therapy (e.g., chemotherapy agent, dmard, or any combination thereof). The present invention also provides a pharmaceutical composition comprising a compound of formula i, a method of manufacturing a pharmaceutical composition comprising a compound of formula i, and a method of administering a pharmaceutical composition comprising a solid form of a compound of formula i..
08/28/14
20140242170

Corticosteroids for the treatment of joint pain


Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production..
08/28/14
20140242073

Cartilage/bone destruction suppressor


An object of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of cartilage or bone seen in rheumatoid arthritis, osteoarthritis, bone metastasis of malignant tumor, or the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor β or a complex of the antibody and a biologically or chemically active substance..
08/21/14
20140235888

(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability


The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
08/21/14
20140235672

Chromene modulators of chemokine receptor activity


Or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein w1, w2, w3, y, z, r2, r3, r3′ and r4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
08/21/14
20140235641

Pyrazole carboxamides as janus kinase inhibitors


The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
08/21/14
20140235543

Methods for isolating and using a subset of cd8 t-cells that are resistant to inhibitors


Methods for identifying a subset of cd8 t cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain cd8 t cells expresses elevated levels of scin and/or pla2g4a, with an elevated level indicative of proliferation of the identified cd8 t cells.


Popular terms: [SEARCH]

Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.4567

4085

0 - 1 - 73